Table 4.
Final diagnoses of benign lesions
| Case # | Final diagnosis | Specimen type | JLCS-JSCC system* |
PSC system** |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NM | AC | SM | ML | NM | AC | N-B-LG | SM | ML | |||
| 1 | Hamartoma | Touch | 3 | 3 | 1 | 0 | 2 | 1 | 4 | 0 | 0 |
| 2 | Hamartoma | Touch | 7 | 0 | 0 | 0 | 2 | 0 | 5 | 0 | 0 |
| 3 | Hamartoma | Touch | 6 | 0 | 1 | 0 | 2 | 0 | 4 | 1 | 0 |
| 4 | Hamartoma | Touch | 7 | 0 | 0 | 0 | 3 | 0 | 4 | 0 | 0 |
| 5 | Hamartoma | Touch | 7 | 0 | 0 | 0 | 2 | 0 | 5 | 0 | 0 |
| 6 | Hamartoma | Touch | 7 | 0 | 0 | 0 | 4 | 0 | 3 | 0 | 0 |
| 7 | Hamartoma | Brush | 1 | 4 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| 8 | SP | Touch | 2 | 1 | 0 | 4 | 0 | 0 | 4 | 0 | 3 |
| 9 | SP | Touch | 5 | 0 | 0 | 2 | 1 | 0 | 4 | 0 | 2 |
| 10 | SP | Touch | 4 | 2 | 0 | 1 | 1 | 0 | 5 | 0 | 1 |
| 11 | SP | Aspiration | 2 | 3 | 0 | 2 | 1 | 0 | 4 | 0 | 2 |
| 12 | SP | Aspiration | 3 | 3 | 0 | 1 | 2 | 1 | 3 | 0 | 1 |
| 13 | PP | Brush | 0 | 1 | 2 | 4 | 0 | 1 | 0 | 2 | 4 |
| 14 | PP | Sputum | 2 | 2 | 0 | 3 | 2 | 2 | 1 | 2 | 0 |
| 15 | SFT | Touch | 2 | 1 | 1 | 3 | 1 | 0 | 4 | 0 | 2 |
| 16 | Meningioma | Touch | 4 | 2 | 1 | 0 | 1 | 0 | 6 | 0 | 0 |
| 17 | Lymphoid hyperplasia | Brush | 6 | 1 | 0 | 0 | 6 | 1 | 0 | 0 | 0 |
NM, negative for malignancy; AC, atypical cells; N-B-LG, neoplastic, benign neoplasm, and low-grade carcinoma; SM, suspicious for malignancy; ML, malignancy; PSC, Papanicolaou Society of Cytopathology; JSCC, Japan Lung Cancer Society; JLCS, Japanese Society of Clinical Cytology; SFT, solitary fibrous tumor; PP, squamous papilloma; SP, sclerosing pneumocytoma.
*
The JLCS and JSCC cytology reporting system for lung carcinoma.
**
The PSC reporting system for lung carcinoma.